Empirical antibiotic therapy for pneumonia in intensive care units: a multicentre, retrospective analysis of potentially pathogenic microorganisms identified by endotracheal aspirates cultures

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 11, 2015, Pages 2295-2305

  Scholte, J B J ^a,b   Duong, H L ^b   Linssen, C ^c   Van Dessel, H ^b   Bergmans, D ^b   van der Horst, R ^c   Savelkoul, P ^b   Roekaerts, P ^b   van Mook, W ^b  

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Zuyderland Medical Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CITROBACTER; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; HAFNIA ALVEI; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; KLUYVERA; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MORGANELLA MORGANII; MULTICENTER STUDY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; RAOULTELLA PLANTICOLA; RETROSPECTIVE STUDY; SERRATIA; STENOTROPHOMONAS MALTOPHILIA; TRACHEAL ASPIRATION PROCEDURE; AGED; BACTERIUM; CLINICAL TRIAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NETHERLANDS; PNEUMONIA, BACTERIAL; TEACHING HOSPITAL; TIME FACTOR; TRACHEA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; FEMALE; HOSPITALS, TEACHING; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NETHERLANDS; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; TIME FACTORS; TRACHEA;

EID: 84944352502     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2482-y     Document Type: Article

References (46)

1. Safdar N, Dezfulian C, Collard HR, Saint S (2005) Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 33(10):2184–2193
2. Melsen WG, Rovers MM, Groenwold RH, Bergmans DC, Camus C, Bauer TT, Hanisch EW, Klarin B, Koeman M, Krueger WA, Lacherade JC, Lorente L, Memish ZA, Morrow LE, Nardi G, van Nieuwenhoven CA, O’Keefe GE, Nakos G, Scannapieco FA, Seguin P, Staudinger T, Topeli A, Ferrer M, Bonten MJ (2013) Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet Infect Dis 13(8):665–671
3. Luna CM, Aruj P, Niederman MS, Garzón J, Violi D, Prignoni A, Ríos F, Baquero S, Gando S; Grupo Argentino de Estudio de la Neumonía Asociada al Respirador group (2006) Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 27(1):158–164
4. Kollef MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134(4):298–314
5. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society (2012) Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33(4):322–327
6. American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171(4):388–416
7. Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G (1987) Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 13(5):342–346
8. Restrepo MI, Peterson J, Fernandez JF, Qin Z, Fisher AC, Nicholson SC (2013) Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care 58(7):1220–1225
9. Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI (2005) Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 31(11):1488–1494
10. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157(2):531–539
11. Gastmeier P, Sohr D, Geffers C, Rüden H, Vonberg RP, Welte T (2009) Early- and late-onset pneumonia: is this still a useful classification? Antimicrob Agents Chemother 53(7):2714–2718
12. Hunter JD (2012) Ventilator associated pneumonia. BMJ 344:e3325
13. Brusselaers N, Labeau S, Vogelaers D, Blot S (2013) Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med 39(3):365–375
14. Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D; VAP Guidelines Committee and the Canadian Critical Care Trials Group (2008) Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care 23(1):138–147
15. Magill SS, Klompas M, Balk R, Burns SM, Deutschman CS, Diekema D, Fridkin S, Greene L, Guh A, Gutterman D, Hammer B, Henderson D, Hess D, Hill NS, Horan T, Kollef M, Levy M, Septimus E, VanAntwerpen C, Wright D, Lipsett P (2013) Developing a new, national approach to surveillance for ventilator-associated events*. Crit Care Med 41(11):2467–2475
16. De Bus L, Saerens L, Gadeyne B, Boelens J, Claeys G, De Waele JJ, Benoit DD, Decruyenaere J, Depuydt PO (2014) Development of antibiotic treatment algorithms based on local ecology and respiratory surveillance cultures to restrict the use of broad-spectrum antimicrobial drugs in the treatment of hospital-acquired pneumonia in the intensive care unit: a retrospective analysis. Crit Care 18(4):R152
17. Scholte JB, van Mook WN, Linssen CF, van Dessel HA, Bergmans DC, Savelkoul PH, Roekaerts PM (2014) Surveillance cultures in intensive care units: a nationwide survey on current practice providing future perspectives. J Crit Care 29(5):885.e7–885.e12
18. European Centre for Disease Prevention and Control (ECDC) (2013) Antimicrobial Resistance Surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2012. Stockholm, Sweden
19. Kariv G, Paul M, Shani V, Muchtar E, Leibovici L (2013) Benchmarking inappropriate empirical antibiotic treatment. Clin Microbiol Infect 19(7):629–633
20. Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G (2013) EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19(2):141–160
21. National Institute for Public Health and the Environment (SWAB) TDWPoAP (2012) Nethmap 2012: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. pp 1–63
22. Canadian Critical Care Trials Group (2006) A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 355(25):2619–2630
23. Medford AR, Husain SA, Turki HM, Millar AB (2009) Diagnosis of ventilator-associated pneumonia. J Crit Care 24(3):473.e1–473.e6
24. Centers for Disease Prevention and Control (CDC); National Healthcare Safety Network (NHSN) (2013) Ventilator-associated events: surveillance protocol. Available online at: http://www.cdc.gov/nhsn/PDFs/pscManual/10-VAE_FINAL.pdf
25. Guyot A, Turton JF, Garner D (2013) Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J Hosp Infect 85(4):303–307
26. Brooke JS (2014) New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther 12(1):1–4
27. van de Voort PHJ, van Saene HKF (2008) Selective digestive tract decontamination in intensive care medicine: a practical guide to controlling infection. Springer, Milan
28. Vegelin AL, Bissumbhar P, Joore JC, Lammers JW, Hoepelman IM (1999) Guidelines for severe community-acquired pneumonia in the western world. Neth J Med 55(3):110–117
29. Vogelaers D, De Bels D, Forêt F, Cran S, Gilbert E, Schoonheydt K, Blot S; ANTHICUS Study Investigators (2010) Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates—a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 35(4):375–381
30. Nair GB, Niederman MS (2015) Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med 41(1):34–48
31. Scholte JB, van Mook WN, Linssen CF (2014) Surveillance cultures in healthcare-associated pneumonia: sense or nonsense? Curr Opin Pulm Med 20(3):259–271
32. Rodvold KA, George JM, Yoo L (2011) Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 50(10):637–664
33. Schacht J, Talaska AE, Rybak LP (2012) Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec (Hoboken) 295(11):1837–1850
34. Swan SK (1997) Aminoglycoside nephrotoxicity. Semin Nephrol 17(1):27–33
35. Kahlmeter G, Dahlager JI (1984) Aminoglycoside toxicity—a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 13(Suppl A):9–22
36. Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y (2003) Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 9(11):1415–1422
37. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41(9):1254–1260
38. de With K, Steib-Bauert M, Straach P, Kern WV (2006) Is there significant regional variation in hospital antibiotic consumption in Germany? Infection 34(5):274–277
39. Chaouch C, Hassairi A, Riba M, Boujaafar N (2014) Association between bacterial resistance and antimicrobial consumption. Ann Biol Clin (Paris) 72(5):555–560
40. Meyer E, Gastmeier P, Deja M, Schwab F (2013) Antibiotic consumption and resistance: data from Europe and Germany. Int J Med Microbiol 303(6–7):388–395
41. Raineri E, Crema L, Dal Zoppo S, Acquarolo A, Pan A, Carnevale G, Albertario F, Candiani A (2010) Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 29(8):1015–1024
42. Merz LR, Warren DK, Kollef MH, Fridkin SK, Fraser VJ (2006) The impact of an antibiotic cycling program on empirical therapy for Gram-negative infections. Chest 130(6):1672–1678
43. Hughes MG, Evans HL, Chong TW, Smith RL, Raymond DP, Pelletier SJ, Pruett TL, Sawyer RG (2004) Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward. Crit Care Med 32(1):53–60
44. Beardsley JR, Williamson JC, Johnson JW, Ohl CA, Karchmer TB, Bowton DL (2006) Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 130(3):787–793
45. Becher RD, Hoth JJ, Rebo JJ, Kendall JL, Miller PR (2012) Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit. Surg Infect (Larchmt) 13(6):352–359
46. Hindler JF, Stelling J (2007) Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis 44(6):867–873